AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1447436
Drug: Rectal (R)
RxNorm normalized name: Rectal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal (R) thermometry
Trial: 3903906
Drug: Pivampicillin, 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin, 700 mg twice daily for seven days
Trial: 3903906
Drug: Metronidazole, 500
RxNorm normalized name: MetroNIDAZOLE, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole, 500 mg twice daily for seven days
Trial: 29336426
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral methotrexate only (Group I)
Trial: 29336426
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral methotrexate plus soak PUVAsol therapy twice weekly for three months (Group II)
Trial: 20629598
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg LD/10 mg MD)
Trial: 20629598
Drug: Prasugrel (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (30 mg LD/7.5 mg MD)
Trial: 20629598
Drug: Prasugrel (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (30 mg LD/5 mg MD)
Trial: 17414229
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg LD/75 mg MD)
Trial: 20629598
Drug: Prasugrel (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (all dosing regimens)
Trial: 17959953
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin 5 mg
Trial: 15865226
Drug: Lamivudine therapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine therapy for 1 year (group 1a, n=19)
Trial: 15865226
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment (group 1a)
Trial: 12464959
Drug: Peanut protein
RxNorm normalized name: peanut protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut protein (various doses)
Trial: 26448178
Drug: Nintedanib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (200 mg twice daily)
Trial: 28380494
Drug: Accelerated up-dosing
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated up-dosing regimen (0.1-0.3-0.5 mL at weekly intervals)
Trial: 28380494
Drug: Conventional up-dosing
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional up-dosing regimen (0.05-0.1-0.2-0.3-0.4-0.5 mL at weekly intervals)
Trial: 25600249
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n = 25)
Trial: 21888993
Drug: Dead Space
RxNorm normalized name: UltiCare 3mL 22G 1-1/2 inch Low Dead Space Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dead Space Loading (DSL) 500 ml
Trial: 3089467
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml iohexol
Trial: 3089467
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml iohexol
Trial: 29713851
Drug: Yiqi Fumai
RxNorm normalized name: Aspergillus fumigatus allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Fumai lyophilized injection (5.2 g) with 250 ml 5% glucose/sodium injection for 7 days
Trial: 29713851
Drug: Standardized western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized western medications (control group) for 7 days
Trial: 26711719
Drug: M‐Ex‐M (morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐Ex‐M (morning and evening metformin doses, with exercise)
Trial: 26711719
Drug: M‐Ex (exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐Ex (exercise with evening metformin dose only)
Trial: 26711719
Drug: Ex‐M (morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex‐M (morning metformin dose only, with exercise)
Trial: 26711719
Drug: M‐M (morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐M (morning and evening metformin doses, without exercise)
Trial: 15349656
Drug: rhEPO 6000IU
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO 6000IU subcutaneously for 3 times a week and Ferrost sulfatis Et vitamini‐medtech 1 tablet per day for 12 days
Trial: 15349656
Drug: Ferrost sulfatis
RxNorm normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrost sulfatis Et vitamini‐medtech (same dose as experimental group)
Trial: 9028716
Drug: oral Etalpha
RxNorm normalized name: Zenalpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral Etalpha (0.25 microgram)
Trial: 9028716
Drug: i.v. and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. and oral 1,25‐dihydroxyvitamin D3
Trial: 9028716
Drug: 1,25‐dihydroxyvitamin D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25‐dihydroxyvitamin D3 and insulin
Trial: 27735028
Drug: Isocaloric diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric diet with 500 mg of metformin twice a day (IM)
Trial: 27735028
Drug: Isocaloric diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric diet with 120 mg of orlistat three times a day (IO)
Trial: 25474455
Drug: Cryosurgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryosurgery and 5-fluorouracil cream 0.5%
Trial: 20512584
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - received 'today's treatment' without additional strength training.
Trial: 8861991
Drug: Implantable insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implantable insulin pump (IIP)
Trial: 16120030
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily insulin (MDI)
Trial: 1735400
Drug: hyperbaric Niphanoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric Niphanoid tetracaine (6 or 10 mg)
Trial: 1735400
Drug: hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric bupivacaine (6 mg)
Trial: 1735400
Drug: hyperbaric Niphanoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric Niphanoid tetracaine (6 mg) with adrenaline
Trial: 1735400
Drug: hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric bupivacaine (6 mg) with adrenaline
Trial: 1735400
Drug: light intravenous
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: light intravenous supplementation with low doses of fentanyl and/or thiopentone
Trial: 30732192
Drug: Furazolidone-based quadruple
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furazolidone-based quadruple therapy (FZD) for 14 days with esomeprazole, bismuth potassium citrate, and amoxicillin
Trial: 30732192
Drug: Clarithromycin-based quadruple
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin-based quadruple therapy (CLA) for 14 days with esomeprazole, bismuth potassium citrate, and amoxicillin
Trial: 24196279
Drug: Intensity modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity modulated radiotherapy (IMRT) with doses of 73.9 Gy (n = 41) and 76.2 Gy (n = 109) delivered in 32 and 33 fractions, respectively.
Trial: 24196279
Drug: Intensity modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity modulated radiotherapy (IMRT) with doses of 73.9 Gy and 76.2 Gy.
Trial: 19915736
Drug: Isoflavone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone (100 mg/day for 4 months)
Trial: 14639137
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (epsilon-ACA) prior to skin incision (bolus 150 mg/kg, followed by an infusion at 15 mg x kg(‐1) x hr(‐1))
Trial: 14639137
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (epsilon-ACA) after heparin (same doses)
Trial: 31377477
Drug: Lapatinib (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1500 mg/day)
Trial: 31377477
Drug: Trastuzumab (common
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (common dose)
Trial: 31377477
Drug: Lapatinib (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1000 mg/day) plus Trastuzumab
Trial: 25581856
Drug: OND OSF
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OND OSF 8 mg (ZUPLENZ)
Trial: 25581856
Drug: OND ODT
RxNorm normalized name: ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OND ODT 8 mg (ZOFRAN)
Trial: 7805426
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg twice daily)
Trial: 19833273
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (5 mg) with 2-minute sitting position after injection
Trial: 19833273
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (5 mg) with 5-minute sitting position after injection
Trial: 19833273
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (5 mg) with 10-minute sitting position after injection
Trial: 8879466
Drug: 25‐mg CMI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25‐mg CMI slow infusion
Trial: 8879466
Drug: 25‐mg CMI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25‐mg CMI tablet
Trial: 31083777
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow (NHF) therapy at 45 L/min
Trial: 25349301
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 plus iniparib 5.6 mg/kg (GCI)
Trial: 25349301
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 (GC)
Trial: 25349301
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m² and carboplatin AUC 2 plus iniparib 5.6 mg/kg (GCI) in second-/third-line treatment
Trial: 22293533
Drug: PHX1766 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHX1766 800 mg twice daily
Trial: 22293533
Drug: PHX1766 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHX1766 (various doses: 50 mg once daily - 1000 mg once daily, 250 mg twice daily)
Trial: 2300922
Drug: Nonsteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroid treatment
Trial: 12739240
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment in cases with persistent canal paresis
Trial: 12739240
Drug: Nonsteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroid treatment in cases with persistent canal paresis
Trial: 10595814
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) prophylaxis (500 mg/kg/d loading from day -6 to -1 and then 100 mg/kg every 3 days from day 3 to 90)
Trial: 10595814
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) prophylaxis
Trial: 29094998
Drug: Nutritional oral
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional oral formula (GS)
Trial: 29094998
Drug: Nutritional oral
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional oral formula (GS) and Control (GC)
Trial: 25946948
Drug: EMLA 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA 5% cream applied to the cervix
Trial: 25946948
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied to the cervix
Trial: 21906521
Drug: Tian Gui
RxNorm normalized name: Tian Qi Root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tian Gui Capsule
Trial: 18710712
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human leukemia inhibitory factor, 150 microg SC twice daily for 7 days
Trial: 17584010
Drug: 50-mg sildenafil
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg sildenafil
Trial: 11275293
Drug: Melatonin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin administration at 0700 h
Trial: 7915672
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline and a breathing mixture of even parts of oxygen and nitrous oxide (Entonox)
Trial: 7915672
Drug: Intravenous ketobemidone
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketobemidone hydrochloride 2.5 mg, midazolam 2.5 mg, and breathing air from a face mask with a demand valve (KHM)
Trial: 31879235
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment plus standard of care (SOC)
Trial: 31879235
Drug: Sham treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatments plus SOC
Trial: 26693193
Drug: Conventional Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Exercise Therapy (CET)
Trial: 23311458
Drug: Employee wellness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Employee wellness programme based on cognitive behaviour therapy (CBT) and weekly supervised exercise classes over six weeks.
Trial: 16139813
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean dose 8.7 +/- 7.1 mg/day)
Trial: 12975627
Drug: Dynamic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic treatment protocol consisting of 4 different subprotocols
Trial: 11076409
Drug: Osmo-adalat 30
RxNorm normalized name: nifedipine 30 MG [Adalat]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmo-adalat 30 mg once daily for 3 weeks
Trial: 11076409
Drug: Cordipin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordipin 10 mg three times a day
Trial: 31036088
Drug: SIB radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SIB radiotherapy concurrent and consolidated with S-1
Trial: 27179999
Drug: Ecopipam (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecopipam (single large dose)
Trial: 25033900
Drug: 20 G vitrectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 G vitrectomy
Trial: 25033900
Drug: 23 G vitrectomy
RxNorm normalized name: pyrantel
DrugBank: Pyrantel (DB11156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23 G vitrectomy
Trial: 25033900
Drug: Diabetic subgroup
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic subgroup (20 G)
Trial: 25033900
Drug: Diabetic subgroup
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic subgroup (23 G)
Trial: 25033900
Drug: Non-diabetic subgroup
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-diabetic subgroup (20 G)
Trial: 25033900
Drug: Non-diabetic subgroup
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-diabetic subgroup (23 G)
Trial: 22686944
Drug: Rivoglitazone 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoglitazone 1.5 mg/day
Trial: 22686944
Drug: Rivoglitazone 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoglitazone 1.0 mg/day
Trial: 22686944
Drug: Rivoglitazone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoglitazone (both doses)
Trial: 18931238
Drug: Gabapentin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1200 mg preoperatively)
Trial: 11956510
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg L‐796568
Trial: 11956510
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg L‐796568
Trial: 7618647
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion at a dose of 0.7 pmol/kg/min for 3 hours
Trial: 385095
Drug: Topical cephradine
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical cephradine (1 g applied to the wound at closure)
Trial: 385095
Drug: Systemic cephradine
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic cephradine (1 g intravenously at induction and 500 mg 4 h later)
Trial: 29546579
Drug: Insulin or
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin or Dapagliflozin
Trial: 23201768
Drug: 15.0 g
RxNorm normalized name: PYRITHIONE ZINC 15.0 g in 1.0 L TOPICAL SHAMPOO [Medaclear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15.0 g egg white protein; 75 kcal
Trial: 23201768
Drug: 17.5 g
RxNorm normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL SPRAY [doTERRA sun]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 g maltodextrin, 78 kcal
Trial: 19960001
Drug: Alginate (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate (three capsules per day, ingested 30 min before the main meal)
Trial: 19960001
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo, three capsules per day, ingested 30 min before the main meal)
Trial: 17408408
Drug: LY517717 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY517717 100 mg
Trial: 17408408
Drug: LY517717 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY517717 125 mg
Trial: 17408408
Drug: LY517717 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY517717 150 mg
Trial: 17408408
Drug: LY517717 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY517717 (all doses)
Trial: 12223253
Drug: CX516 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX516 (300 mg tid to 900 mg tid over 4 weeks)
Trial: 8744964
Drug: Sequential presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential presentation at test
Trial: 15764422
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg fluoxetine
Trial: 6388247
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg clomipramine
Trial: 28697780
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration of analgesia with steroid (LIA)
Trial: 26032118
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block (ropivacaine 0.5%, 20 ml on each side)
Trial: 26032118
Drug: Sham block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham block (isotonic saline 0.9%, 20 ml on each side)
Trial: 22381601
Drug: Betamethasone 12-hour
RxNorm normalized name: betamethasone 0.12 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 12-hour dosing interval
Trial: 22381601
Drug: Betamethasone 24-hour
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone 24-hour dosing interval
Trial: 16222900
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg and Ramipril 10 mg
Trial: 8565983
Drug: Azithromycin (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (once daily for three days)
Trial: 8565983
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (thrice daily for ten days)
Trial: 2178656
Drug: Single heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single heparin bolus of 10,000 units (protocol I)
Trial: 2178656
Drug: Heparin bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin bolus of 10,000 units plus continuous infusion of 2000 units/hour (protocol II)
Trial: 2178656
Drug: Heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin infusion at the rate of 2000 units/hour for 24 hours post-angioplasty
Trial: 23577619
Drug: Azithromycin and
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin and chloroquine fixed-dose combination (AZCQ)
Trial: 19740297
Drug: Captopril (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (0.2 mg/kg/day) for 12 months